CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growth in the ageing population and the associated increase in the prevalence of
Parkinson’s disease
4.1.2. Government funding for research
4.2. Market Restraints & Challenges
4.2.1. Availability of alternative treatments
4.3. Market Opportunities
4.3.1. Patent expiry of branded drugs
4.3.2. Strong drug pipeline
CHAPTER 5. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET – BY
DRUG TYPE
5.1. Carbidopa/Levodopa
5.2. Dopamine Receptor Agonists
5.3. Mao Inhibitors
5.4. Comt Inhibitors
5.5. Anticholinergics
5.6. Other Drugs
CHAPTER 6. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET – BY
DISTRIBUTION CHANNEL
6.1. Hospital pharmacies
6.2. Retail pharmacies
6.3. Online pharmacies
CHAPTER 7. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET – BY
PATIENT CARE
7.1. Hospitals
7.2. Clinics
CHAPTER 8. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET - BY
GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET -
COMPANY PROFILES
9.1. GlaxoSmithKline PLC
9.2. Merck & Co., Inc.
9.3. Novartis International AG
9.4. Teva Pharmaceuticals Industries
9.5. Boehringer Ingelheim GmbH
9.6. Impax Pharmaceuticals
9.7. AbbVie AG
9.8. Bausch Health Companies Inc.
9.9. Lund beck
9.10. Sun Pharmaceuticals Industries Ltd.
9.11. Wockhardt Ltd.
9.12. Acadia Healthcare
9.13. UCB
9.14. Biogen Inc.
9.15. Pfizer Inc.
CHAPTER 10. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET -
COMPETITIVE LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
